Sava Infond’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sava Infond’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$195K	Hold	3,250	–	–	0.01%	189
2026 Q2	$186K	Hold	3,250	–	–	0.01%	190
2026 Q1	$184K	Hold	3,250	–	–	0.03%	187
2025 Q4	$193K	Hold	3,250	–	–	0.03%	173
2025 Q3	$176K	Hold	3,250	–	–	0.03%	176
2025 Q2	$179K	Hold	3,250	–	–	0.03%	176
2025 Q1	$230K	Hold	3,250	–	–	0.04%	162
2024 Q4	$214K	Buy	+3,250	New	+$218K	0.04%	169

Other funds holding BMRN

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Sava Infond's BMRN Position: Q3 2026 in Review

Sava Infond held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 3,250 shares worth $195K. The position accounts for 0.01% of the portfolio, ranked #189.

Sava Infond first reported a position in BMRN in Q4 2024 and has held it in 8 quarters since. The position peaked at $230K in Q1 2025. 249 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Sava Infond held 3,250 shares of BioMarin Pharmaceuticals worth $195K as of Q3 2026.
Sava Infond left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
BioMarin Pharmaceuticals made up 0.01% of Sava Infond's portfolio in Q3 2026, its #189 holding.
Sava Infond first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Sava Infond's BioMarin Pharmaceuticals position peaked at $230K in Q1 2025.
249 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Sava Infond's 13F filing for Q3 2026, filed 28 Oct 2026.